Other  ||| S:0 E:6 ||| JJ
new  ||| S:6 E:10 ||| JJ
targets  ||| S:10 E:18 ||| NNS
Despite  ||| S:18 E:26 ||| IN
improvements  ||| S:26 E:39 ||| NNS
in  ||| S:39 E:42 ||| IN
surgical  ||| S:42 E:51 ||| JJ
and  ||| S:51 E:55 ||| CC
diagnostic  ||| S:55 E:66 ||| JJ
techniques ||| S:66 E:76 ||| NNS
,  ||| S:76 E:78 ||| ,
the  ||| S:78 E:82 ||| DT
outcome  ||| S:82 E:90 ||| NN
for  ||| S:90 E:94 ||| IN
women  ||| S:94 E:100 ||| NNS
with  ||| S:100 E:105 ||| IN
advanced  ||| S:105 E:114 ||| JJ
epithelial  ||| S:114 E:125 ||| JJ
ovarian  ||| S:125 E:133 ||| JJ
cancer  ||| S:133 E:140 ||| NN
remains  ||| S:140 E:148 ||| VBZ
poor ||| S:148 E:152 ||| JJ
.  ||| S:152 E:154 ||| .
Recent  ||| S:154 E:161 ||| JJ
developments  ||| S:161 E:174 ||| NNS
in  ||| S:174 E:177 ||| IN
the  ||| S:177 E:181 ||| DT
understanding  ||| S:181 E:195 ||| NN
of  ||| S:195 E:198 ||| IN
cancer  ||| S:198 E:205 ||| NN
biology  ||| S:205 E:213 ||| NNS
have  ||| S:213 E:218 ||| VBP
led  ||| S:218 E:222 ||| VBN
to  ||| S:222 E:225 ||| TO
an  ||| S:225 E:228 ||| DT
explosion  ||| S:228 E:238 ||| NN
in  ||| S:238 E:241 ||| IN
clinical  ||| S:241 E:250 ||| JJ
trials  ||| S:250 E:257 ||| NNS
using  ||| S:257 E:263 ||| VBG
targeted  ||| S:263 E:272 ||| VBN
agents ||| S:272 E:278 ||| NNS
.  ||| S:278 E:280 ||| .
In  ||| S:280 E:283 ||| IN
women  ||| S:283 E:289 ||| NNS
with  ||| S:289 E:294 ||| IN
epithelial  ||| S:294 E:305 ||| JJ
ovarian  ||| S:305 E:313 ||| JJ
cancer ||| S:313 E:319 ||| NN
,  ||| S:319 E:321 ||| ,
antiangiogenic  ||| S:321 E:336 ||| JJ
agents  ||| S:336 E:343 ||| NNS
have  ||| S:343 E:348 ||| VBP
led  ||| S:348 E:352 ||| VBN
the  ||| S:352 E:356 ||| DT
field ||| S:356 E:361 ||| NN
.  ||| S:361 E:363 ||| .
There  ||| S:363 E:369 ||| EX
are ||| S:369 E:372 ||| VBP
,  ||| S:372 E:374 ||| ,
however ||| S:374 E:381 ||| RB
,  ||| S:381 E:383 ||| ,
other  ||| S:383 E:389 ||| JJ
novel  ||| S:389 E:395 ||| NN
targets  ||| S:395 E:403 ||| NNS
and  ||| S:403 E:407 ||| CC
agents  ||| S:407 E:414 ||| NNS
undergoing  ||| S:414 E:425 ||| VBG
evaluation ||| S:425 E:435 ||| NN
.  ||| S:435 E:437 ||| .
This  ||| S:437 E:442 ||| DT
review  ||| S:442 E:449 ||| NN
focuses  ||| S:449 E:457 ||| VBZ
on  ||| S:457 E:460 ||| IN
some  ||| S:460 E:465 ||| DT
of  ||| S:465 E:468 ||| IN
these  ||| S:468 E:474 ||| DT
newer  ||| S:474 E:480 ||| JJR
approaches  ||| S:480 E:491 ||| NNS
to  ||| S:491 E:494 ||| TO
targeted  ||| S:494 E:503 ||| JJ
therapy  ||| S:503 E:511 ||| NN
highlighting  ||| S:511 E:524 ||| VBG
the  ||| S:524 E:528 ||| DT
importance  ||| S:528 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
trial  ||| S:542 E:548 ||| NN
design  ||| S:548 E:555 ||| NN
and  ||| S:555 E:559 ||| CC
incorporation  ||| S:559 E:573 ||| NN
of  ||| S:573 E:576 ||| IN
biomarkers  ||| S:576 E:587 ||| NN
as  ||| S:587 E:590 ||| IN
we  ||| S:590 E:593 ||| PRP
move  ||| S:593 E:598 ||| VBP
forward  ||| S:598 E:606 ||| RB
into  ||| S:606 E:611 ||| IN
the  ||| S:611 E:615 ||| DT
era  ||| S:615 E:619 ||| NN
of  ||| S:619 E:622 ||| IN
personalized  ||| S:622 E:635 ||| JJ
medicine ||| S:635 E:643 ||| NN
.  ||| S:643 E:645 ||| .
